InflaRx's Marketing Authorization Application (MAA) For Vilobelimab For Treatment Of Critically Ill COVID-19 Patients Under Review By European Medicines Agency (EMA)
Portfolio Pulse from Benzinga Newsdesk
InflaRx's Marketing Authorization Application (MAA) for Vilobelimab, a treatment for critically ill COVID-19 patients, is currently under review by the European Medicines Agency (EMA).
August 30, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InflaRx's MAA for Vilobelimab is under review by the EMA. A positive outcome could boost the company's stock.
The review of InflaRx's MAA for Vilobelimab by the EMA is a crucial step for the company. If the EMA approves the application, it could lead to increased sales and revenue for InflaRx, which would likely have a positive impact on the company's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100